Format

Send to

Choose Destination
J Alzheimers Dis. 2016;51(2):333-8. doi: 10.3233/JAD-151078.

Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.

Author information

1
Institute for Life Sciences, University of Southampton, UK.
2
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.
3
Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Japan.
4
Biomarkers Research Program, Department of Biochemistry College of Science, King Saud University, KSA.
5
Prince Mutaib Chair for Biomarkers of Osteoporosis, Department of Biochemistry King Saud University, KSA.
6
Department of Neurology, National Cerebral and Cardiovascular Center, Japan.
7
Cancer Sciences, Faculty of Medicine, University of Southampton, UK.

Abstract

The aim of this study was to examine hemisphere asymmetry of response to pharmacologic treatment in an Alzheimer's disease mouse model using cilostazol as a chemical stimulus. Eight-month-old mice were assigned to vehicle or cilostazol treatment for three months and hemispheres were analyzed using quantitative proteomics. Bioinformatics interpretation showed that following treatment, aggregation of blood platelets significantly decreased in the right hemisphere whereas neurodegeneration significantly decreased and synaptic transmission increased in the left hemisphere only. Our study provides novel evidence on cerebral laterality of pharmacologic activity, with important implications in deciphering regional pharmacodynamic effects of existing drugs thus uncovering novel hemisphere-specific therapeutic targets.

KEYWORDS:

Alzheimer’s disease; cilostazol; hemisphere asymmetry; mass spectrometry pharmacology; pharmacodynamics; pharmacoproteomics

PMID:
26836196
PMCID:
PMC4927832
DOI:
10.3233/JAD-151078
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center